ADMA Biologics (ADMA) Stock Forecast & Price Target
Score
ADMA Biologics, Inc. price target
| ADMA | |
|---|---|
| Low | $17.00 |
| Average | $18.67 |
| High | $21.00 |
| Upside vs current price | +36.5% |
The average target of $18.67 is +36.5% versus the current ADMA price of $13.68.
ADMA Biologics, Inc. analyst ratings
| Rating | Analysts |
|---|---|
| Strong buy | 1 |
| Buy | 2 |
| Hold | 1 |
| Sell | 0 |
| Strong sell | 0 |
| Consensus | Buy |
4 analysts cover ADMA.
ADMA Biologics, Inc. EPS and revenue estimates
Published annual figures for ADMA on this page are 2026 EPS $0.80, 2027 EPS $0.94. Coverage under three analysts is omitted.
| Fiscal year | EPS estimate | Revenue estimate |
|---|---|---|
| 2026 | $0.80 | $535.36M |
| 2027 | $0.94 | $629.55M |
Is ADMA Biologics, Inc. a buy or sell?
Of the 4 analysts covering ADMA Biologics, Inc., 3 rate it a buy (1 strong buy and 2 buy), 1 rates it a hold, and 0 rate it a sell (0 sell and 0 strong sell).
The ADMA consensus label is Buy, beside 3 buy-side ratings and 0 sell-side ratings.
The average target of $18.67 implies +36.5% versus the current price of $13.68.
The ADMA rating block is 4 published views with a Buy label. It does not tell you whether to buy or sell.
Reading the ADMA Biologics, Inc. forecast
the ADMA Biologics, Inc. is priced by the street between $17.00 and $21.00, average $18.67.
The gap from the $13.68 price to the ADMA average is +36.5%.
The ADMA rating mix is lopsided rather than split: 3 of 4 analysts are on the buy side, 1 is at hold, and 0 are on the sell side, and the published consensus is Buy.
the ADMA Biologics, Inc. has a rising EPS path, $0.80 for 2026 and $0.94 for 2027.
With 4 analysts on ADMA, the average is a small sample.
ADMA Biologics, Inc. forecast questions
What is the ADMA price target?
The published range for ADMA is $17.00 to $21.00, with an average of $18.67. That average is +36.5% versus the current price of $13.68.
Is ADMA Biologics, Inc. a buy or sell?
Of the 4 analysts covering ADMA Biologics, Inc., 3 rate it a buy, 1 rates it a hold, and 0 rate it a sell. The consensus is Buy, leaving ADMA at 3 buy ratings, 1 holds, and 0 sells.
What is the EPS estimate for ADMA Biologics, Inc.?
Analyst EPS estimates for ADMA Biologics, Inc.: 2026 $0.80, 2027 $0.94.
What is the revenue estimate for ADMA Biologics, Inc.?
Analyst revenue estimates for ADMA Biologics, Inc.: 2026 $535.36M, 2027 $629.55M.
How many analysts cover ADMA?
4 analysts cover ADMA. Their consensus on ADMA is Buy, across those 4.